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Abstract
Background: Few reports have examined the association between unemployment and work disability in Chronic
Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). This study explored the key determinants of work disability
in a CFS/ME cohort.
Methods: A community-based prospective study included 1086 CFS/ME patients aged 18–65 years. Demographic
and clinical characteristics and outcome measures were recorded. Multiple linear regression analysis was performed
to identify key risk indicators of work disability.
Results: Four hundred and fifty patients with CFS/ME were employed (41.4%) and 636 were unemployed (58.6%).
Older age at pain onset (OR: 1.44; 95% CI: 1. 12–1.84, autonomic dysfunction (OR: 2.21; 95% CI: 1.71–2.87),
neurological symptom (OR: 1.66; 95% CI: 1. 30–2.13) and higher scores for fatigue (OR: 2.61; 95% CI: 2.01–
3.39), pain (OR: 2.09; 95% CI: 1.47–2.97), depression (OR: 1.98; 95% CI: 1. 20–3.26), psychopathology (OR: 1.98;
95% CI: 1.51–2.61) and sleep dysfunction (OR: 1.47; 95% CI: 1. 14–1.90) were all associated with a higher risk
of work disability due to illness.
Conclusions: Using an explanatory approach, our findings suggest that unemployment is consistently associated with
an increased risk of work disability due to CFS/ME, although further more rigorous research is now needed to help in
targeting interventions at the workplace.
Keywords: Chronic fatigue syndrome, Myalgic encephalomyelitis, Work disability, Unemployment, Quality of life,
Comorbidity
Key points
1 - This study examined the effect of unemployment
on work disability due to cardinal symptoms and
comorbidity in individuals with CFS/ME.
2 - Work disability is common in adult patients with
CFS/ME. Further investigations should aim to
define the phenotype of patients who would benefit
from specific interventions, and should develop
clinically relevant objective measures.
3 - The results may provide useful guidance for the
design of rehabilitation strategies to counter work
disability, raise quality of life, and reduce future
productivity losses in those CFS/ME individuals of
Europe.
4 - Targeting chronic fatigue-associated symptoms
through the design of public health care and occu-
pational policies may help to reduce the burden of
CFS/ME in Europe.
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jesus.castro@vhir.org
†Jesús Castro-Marrero and Mónica Faro are contributed equally as first
authors.
1CFS/ME Unit, Vall d’Hebron University Hospital Research Institute, Universitat
Autónoma de Barcelona, Passeig de Vall d’Hebron 119-129, E-08035
Barcelona, Spain
Full list of author information is available at the end of the article
Castro-Marrero et al. BMC Public Health          (2019) 19:840 
https://doi.org/10.1186/s12889-019-7225-z
Background
Chronic fatigue syndrome/myalgic encephalomyelitis
(CFS/ME) is a serious, complex, multisystem, neuroim-
mune condition with a variety of clinical presentations
that affect millions of people all over the world. CFS/ME
is a debilitating illness that substantially impairs profes-
sional, recreational, social, and educational activities.
Despite substantial efforts by researchers to unravel the
pathomechanisms that underlying to CFS/ME, no
known cause has been identified, no diagnostic tests
have been established, and no FDA-approved drugs are
available for effective treatment [1]. CFS/ME is charac-
terized by debilitating chronic fatigue, widespread pain,
post-exertional malaise, unrefreshing sleep, cognitive im-
pairments and autonomic dysfunction, which affect daily
physical and work activity. Often patients do not receive
appropriate treatment and are ineligible for the disability
benefits awarded to other chronic diseases, in spite of
the significant social burden of the condition [2]. So far,
the influence of employment status on work disability in
CFS/ME individuals in Spain has not been fully investi-
gated. Nor have any epidemiological studies have been
conducted in this country, though elsewhere the esti-
mated prevalence ranges between 0.07 and 2.6% of the
general population [3–5]. The 1994 CDC/Fukuda defin-
ition for CFS/ME requires that individuals experience 6
months of fatigue not alleviated by rest, is of new or def-
inite onset and is accompanied by at least four of eight
core symptoms present for at least six consecutive
months [6]. A new definition of CFS/ME excluding psy-
chiatric cases was proposed in the Canadian consensus
criteria [7]; this useful complement to the 1994 CDC/
Fukuda case definition. Diagnosis is difficult for physi-
cians who are not familiar with the illness. For this rea-
son, many CFS/ME patients may initially be
misdiagnosed with other fatiguing illnesses (the opposite
is also true; many patients with other complex fatiguing-
related conditions have been misdiagnosed with CFS
and/or ME). However, by following standard medical
procedures – taking a careful/thorough history, ruling
out similar fatigue-related illnesses, noting signs and
symptoms typical of the condition, any medications the
patient is currently taking, any other factors that might
influence the severity or persistence of the fatigue, and
ordering tests that are usually abnormal in CFS/ME pa-
tients, any physician can diagnose the disease. CFS/ME
is also associated with comorbid health conditions.
These comorbidities very in terms of prevalence and
severity, but are higher than in patients without CFS/ME
[8, 9]. The study of CFS/ME includes assessment of
fatigue, pain, anxiety-depression, psychopathological
symptoms, sleep dysfunction and quality of life (QoL)
using validated self-administered questionnaires. QoL in
CFS/ME individuals is significantly worse than in other
chronic diseases [10]. CFS/ME is associated with signifi-
cant alterations in work and family life; and impact their
economic wellbeing [11–13]. To date, few studies have
attempted to explore the effects of work disability on
employment status in CFS/ME, and most of the studies
carried out were underpowered or were conducted in
highly selected populations [14, 15]. The present study
aims to identify key factors of work disability in a large
Spanish CFS/ME sample in order to design interventions
for overcoming them.
Methods
Study setting and participants
This large community-based prospective cohort study
included 1086 potentially eligible patients who fulfilled
the 1994 CDC/Fukuda definition and 2003 Canadian
Consensus Criteria for CFS and ME, respectively [6, 7].
Only CFS/ME subjects of working-age (i.e., adults aged
18–65 years) and recruited at a single outpatient
tertiary-referral center (CFS/ME Unit, Vall d’Hebron
University Hospital, Barcelona, Spain) over a 10 year
follow-up period beginning in January 2008 were in-
cluded. Data source for baseline information was pro-
vided from the Spanish National Health System (SNHS)
based on the local CFS/ME clinical data register. Exclu-
sion criteria were psychiatric conditions, cardiovascular,
hematological, infectious, endocrine and metabolic dis-
orders, autoimmune conditions, pregnancy or breast-
feeding, current drug/substance abuse, and smoking. All
procedures performed were reviewed and approved by
the Human Research Ethics Committee of the Vall
d’Hebron University Hospital, Barcelona, Spain. Partici-
pants were fully informed of the study procedures, and
provided written informed consent prior to study initi-
ation. The study was conducted in accordance with the
Declaration of Helsinki, no extra procedures were per-




We recorded demographic and clinical variables such as
age, gender, and comorbid health conditions. We also
assessed the characteristics of fatigue and pain (apparent
cause, age at onset, course and time of evolution). Illness
duration, marital status, type of profession and educa-
tional level were also recorded as is categorized in
Table 1. According to the definition of SNHS through
the Ministry of Employment and Social Security, partici-
pants who self-reported that they had been out of work
for 1 year or more were classified as unemployed. Those
who indicated they were “employed for wages” or “self-
employed” were classified as employed.
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Table 1 Baseline socio-demographic and clinical characteristics based on employment status of the study population (n = 1086)
Employed (n = 450) Unemployed (n = 636) P-valueb
Gender 0.959
Female 405 (90.0) 573 (90.1)
Male 45 (10.0) 63 (9.9)
Age group, years 0.004**
≤ 40 123 (27.3) 130 (20.4)
41–50 182 (40.4) 246 (38.7)
> 50 145 (32.2) 260 (40.9)
Age at onset, years 0.002**
Fatigue 36 ± 10.3 37.8 ± 9.5
Pain 36.6 ± 10.2 38.4 ± 9.6
Illness duration, years 9 ± 7.6 10.5 ± 8.6 0.839
Comorbid conditionsa
Fibromyalgia 207 (46.0) 394 (62.0) < 0.001***
Degenerative vertebral disease 220 (49.0) 376 (59.3) 0.001***
Epicondylitis 187 (41.6) 310 (48.9) 0.018*
Ligamentous hyperlaxity 130 (28.9) 235 (37.1) 0.005**
Multiple chemical hypersensitivity 135 (30.1) 230 (36.2) 0.035**
Carpal tunnel syndrome 62 (13.8) 122 (19.2) 0.018*
Marital status 0.028**
Married 272 (60.6) 428 (67.4)
Single 107 (23.8) 107 (16.9)
Separated/divorced 60 (13.4) 90 (14.2)
Widow 10 (2.2) 10 (1.6)
Profession < 0.001***
Unskilled work 213 (47.3) 262 (41.2)
Skilled work 105 (23.3) 179 (28.1)
Administrative/office work 92 (20.4) 111 (17.5)
Education/teaching 14 (3.1) 15 (2.4)
Self-employed 7 (1.6) 7 (1.1)
Liberal profession 16 (3.6) 23 (3.6)
Arts and crafts 1 (0.2) 5 (0.8)
Student 2 (0.4) 1 (0.2)
Housewife 0 (0) 33 (5.2)
Educational level 0.506
Elementary (primary) school 69 (15.3) 109 (17.1)
Graduate 66 (14.7) 105 (16.5)
High school/vocational training 188 (41.8) 248 (39.0)
University 126 (28.0) 169 (26.6)
Literate 1 (0.2) 5 (0.8)




a Because participants may report more than one comorbid illness, column numbers do not add up to the total sample. b Data analysis was performed using Chi-
square test for categorical variables
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Confounders
As potential confounders, we included gender, age, mari-
tal status, education level, neurocognitive symptoms and
muscular skeletal pain including the pain onset at base-
line which were examined in relation to their effects on
the results. Information on gender, age, marital status’
and ‘vocational education’ was obtained from the regis-
try. Applying the ISCED classification, all persons were
grouped into married, single, separated/divorced or
widow for marital status and primary, secondary and ter-
tiary education, respectively. Because musculoskeletal
disorders and related pain are known causes of disability,
we used self-reported VAS ‘chronic high or low back
pain’ as indicator for co-morbid conditions. Persons
were considered exposed when they perceived pain ‘all
the time’, and persons were considered unexposed when
they perceived ‘less pain’.
Measures
All eligible participants completed the following self-
reported outcome questionnaires.
Visual analog scale (VAS)
Patients were asked to self-report their pain/fatigue
symptom intensity on a visual analog scale (VAS), a con-
tinuous single-item scale (one-dimensional measure for
pain/fatigue intensity) comprising a 10 cm-length line
ranging from “no pain/fatigue” (score of 0 cm) to “pain/
fatigue as bad as it could be” or “worst imaginable pain/
fatigue” (score of 10 cm). Patients mark the VAS line at
the point that represents their “current” symptom inten-
sity “in the last 24 hours”. Higher scores indicated
greater pain/fatigue intensity [16].
Fatigue impact Scale-40 (FIS-40)
The FIS-40 assesses the effects of fatigue on QoL and
examines the perception of functional limitations due to
fatigue in the last month. It reflects the perceived impact
of fatigue in three subscales: cognitive functioning (10
items), physical functioning (10 items), and psychosocial
functioning (20 items). Each item is scored from 1 (ab-
sence of problem) to 4 (maximum problem). The max-
imum score is 160 points. Scores over 120 points were
considered as clinically severe fatigue symptoms, and a
score of 120 points or below was defined as mild/moder-
ate symptoms. Internal consistency was high for overall
scores and the three subscales (Cronbach’s α ≥ 0.87).
Test–retest reliability was high (0.72–0.83), as was con-
vergent validity for CFS/ME individuals and healthy
controls [17].
Daily-fatigue impact Scale-8 (D-FIS-8)
The D-FIS-8 was developed from the FIS-40 question-
naire to measure the response to daily changes in fatigue
intensity. It comprises seven items with Likert type re-
sponses with seven possibilities of increasing intensity,
scoring from 1 to 7. The total score is the sum of all the
items. This 8-item D-FIS has demonstrated good corre-
lations with CFS/ME symptom ratings and other general
health ratings [18].
Short form 36-item health survey (SF-36)
This generic self-report scale is used to assess health-
related quality of life (HR-QOL), measuring physical and
mental functioning within the context of an individual’s
health status. It comprises 36 questions which explore
eight dimensions of the state of health: physical func-
tioning (limitation of physical activities of daily life),
physical role functioning (interference at work), bodily
pain, general health perception, vitality, social function-
ing (interference in habitual social life), emotional role
(interference in work due to emotional problems) and
mental health (depression, anxiety, self-control and gen-
eral well-being). The SF-36 produces two summary com-
ponents, one physical and one mental, each one
generated by combining the scores of each dimension.
SF-36 scores range from 0 to 100, with scores below 50
indicating a more disabling effect of the individual’s
health on his/her functioning [19].
Symptom CheckList-90-revised (SCL-90-R)
This inventory evaluates a wide range of self-reported
psychological problems and psychopathological symp-
toms. Each of the 90 items on the questionnaire is
assessed on a five-point rating scale (0–4) and is
evaluated and interpreted based on nine primary symp-
tom domains and three global psychological distress in-
dices. Primary symptom dimensions are: somatization,
obsessive-compulsive, interpersonal sensitivity, depres-
sion, anxiety, hostility, phobic anxiety, paranoid ideation
and psychotics, and the global indices are: global severity
index, positive symptom distress index, and overall posi-
tive symptoms. Total scores of 65 or over indicate
people at mild/moderate symptom risk, and scores of 80
or more indicate the presence of severe psychopatho-
logical symptoms. The questionnaire performs an initial
evaluation of patients as an objective assessment of the
symptom, to measure the patient’s progress (before, dur-
ing and after treatment) and treatment outcomes; in
clinical trials, it is used also to measure changes in
symptoms such as depression and anxiety. More than
1000 studies have been conducted demonstrating the re-
liability, validity, and utility of the instrument [20].
Hospital anxiety and depression scale (HADS)
The HADS is a 14-item scale including two subscales,
anxiety and depression, each one comprising seven state-
ments, in which the frequency or intensity of baseline
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anxiety (HADS-A) and depression (HADS-D) symp-
toms is measured on a four-point Likert scale (from 0
to 3). The total score on each subscale is obtained by
adding together the items, and thus ranges from 0 to
21. A score ≥ 8 on HADS indicates the presence of
clinically significant anxiety/depression symptoms.
Scores of 0–7 indicate the absence of significant mor-
bidity. The severity of anxiety/depression symptoms
was classified as “mild/moderate” (HADS ≥8 and ≤
14), or “severe” (HADS ≥15 and ≤ 21) [21].
Pittsburgh sleep quality index (PSQI)
The PSQI is considered one of the best scales for quanti-
tative assessment of the quality of sleep in a wide variety
of conditions. It comprises 24 questions, of which 19
must be answered by the subject and the remaining five
by the roommate (if applicable). After correction, seven
scores are obtained that provide information on various
aspects of sleep quality (subjective sleep quality, sleep la-
tency, sleep duration, habitual sleep efficiency, sleep dis-
turbances, use of sleeping medication, and daytime
dysfunction). Each component is scored from 0 (no
problems) to 3 points (serious sleep problems). The glo-
bal PSQI score ranges from 0 to 21 points, with a global
PSQI score ≥ 5 indicating poor sleep quality or ‘poor
sleepers’ [22].
Statistical analysis
The descriptive variables analyzed were employment
status at the time of diagnosis (employed, and un-
employed due to sick leave or disability) as dependent
variable, and demographic and clinical variables (age,
sex, comorbid health conditions, marital status, profes-
sion, and educational level) as independent variables.
The sample was described by means of relative and ab-
solute frequencies, dispersion and central tendency:
mean, median, standard deviation, minimum, maximum
and the valid number of cases. Sample homogeneity was
checked by the Kolmogorov-Smirnov test to ensure nor-
mal distribution and the Levene’s test to verify the
homogeneity of variances. In order to facilitate the ana-
lysis, the continuous variables (age at onset of pain and
fatigue, VAS for fatigue and pain, muscular, cognitive,
neurological, autonomic and immune symptoms, and all
self-reported outcome measures) were categorized ac-
cording to their median values. The association between
categorical variables was analyzed using the Pearson
correlation coefficient (χ2-test). The comparisons of
means between employed and unemployed participants
for continuous variables were analyzed using the non-
parametric Mann-Whitney U test for independent sam-
ples. To determine risk indicators associated with work
disability, a univariate logistic regression analysis was
performed for each of the variables. Multivariate analysis
was performed using backward logistic regression ana-
lysis, keeping age and gender as dependent variables.
The type I error was set at 5% based on a standardized
normal deviation (p < 0.05) with a 95% CI. All statistical
analyses were performed using SPSS v21.0 software.
Results
Participant characteristics
Participants’ socio-demographic and clinical characteris-
tics and employment status is summarized in Table 1. In
all, 450 participants were in employment (41.4%) and 636
unemployed (58.6%), of whom 418 (66%) were on sick
leave and 218 (34%) had an illness-related disability. The
majority of patients were women (90% of those in employ-
ment and 90.1% of those unemployed) without any signifi-
cant differences between the two groups (Table 1). As
shown in Table 1, 27.3% of those in employment were
aged ≤40 years compared to 20.4% of the unemployed,
and 32.2% of those in employment were over 50 years
compared to 40.9% of the unemployed (p = 0.004). Re-
garding professional activity, 47.3% of those in employ-
ment and 41.2% of the unemployed were unskilled, while
23.3% of those in employment were skilled workers and
28.1% of the unemployed (p < 0.001). In patients in em-
ployment, the age of onset of fatigue and pain was lower
than in the unemployed (mean age ± SD (years): 36.0 ±
10.3 vs. 37.8 ± 9.5 and 36.6 ± 10.2 vs. 38.4 ± 9.5; p = 0.002
for both) respectively. Table 1 also shows that the un-
employed patients presented more comorbidities. The co-
morbidities that differed the most between the groups
were fibromyalgia (p < 0.001), degenerative vertebral dis-
ease (p = 0.001), epicondylitis (p = 0.018), ligamentous
hyperlaxity (p = 0.005) and carpal tunnel syndrome (p =
0.018). There were no significant differences between the
groups in terms of family or personal history of illness, ap-
parent cause, or form of onset of fatigue and pain (data
not shown).
Influence of self-reported symptom clusters and work
status among participants
Regarding the self-reported symptom clusters, un-
employed patients had more muscular, cognitive,
neurological, autonomic and immunological symptoms
than those in employment (p < 0.001 across all
groups) (Table 2).
Potential predictors assessed by self-reported measures
and work status using the univariate model
Table 3 summarizes the mean scores for outcome mea-
sures according to employment status among partici-
pants. In the pain and fatigue VAS, unemployed patients
obtained higher scores (p = 0.002). Unemployed patients
obtained significantly higher scores on the two fatigue
impact questionnaires, D-FIS-8 and FIS-40 (in the latter,
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Table 2 Data on self-reported symptom clusters in the sample (n = 1086)
Symptoms Employed (n = 450) Unemployed (n = 636) p-valuea
Muscular
Generalized chronic pain 380 (84.4) 583 (91.7) < 0.001***
Muscle weakness 439 (97.6) 619 (97.3) 0.815
Post-exertional malaise 441 (98.0) 630 (99.1) 0.142
Difficulty performing fine movements due to pain 389 (86.4) 553 (86.9) 0.809
Marked muscle contractures 396 (88.0) 567 (89.2) 0.555
Myoclonic 156 (34.7) 264 (41.6) 0.023*
Falls due to loss of tone 74 (16.4) 159 (25.0) 0.001***
Cognitive
Concentration impairments 424 (94.2) 616 (96.9) 0.034*
Alterations in short-term memory consolidation 410 (91.1) 610 (95.9) 0.001***
Alterations during task planning 355 (78.9) 577 (90.7) < 0.001***
Difficulty with calculation 385 (85.6) 584 (91.8) 0.001***
Difficulty redding 402 (89.3) 594 (93.4) 0.017*
Confusion and forgetfulness 361 (80.2) 560 (88.1) < 0.001***
Temporal-spatial disorientation 282 (62.7) 481 (75.6) < 0.001***
Episodes of nominal aphasia 382 (84.9) 565 (88.8) 0.055
Auditory and visual agnosia 133 (29.6) 257 (40.4) < 0.001***
Neurological
Ataxia and/or dissymmetry 331 (73.6) 514 (80.8) 0.005**
Sensory hypersensitivity 403 (89.6) 582 (91.5) 0.275
Visual alterations 290 (64.4) 472 (74.2) 0.001***
Motor incoordination, with or without falls 339 (75.3) 511 (80.3) 0.048*
Autonomic
Dizziness or cephalic instability 356 (79.1) 552 (86.8) 0.001***
Vertigo 322 (71.6) 496 (78.0) < 0.001***
Orthostatic hypotension 342 (76.0) 512 (80.5) 0.009**
Lipothymia 80 (17.8) 171 (26.9) 0.017*
Syncope 48 (10.7) 98 (15.4) 0.015*
Frequent palpitations 313 (69.6) 495 (77.8) 0.074
Tremor 171 (38.0) 314 (49.4) < 0.001***
Profuse sweating 285 (63.3) 451 (70.9) 0.024*
Altered bowel habits 296 (65.8) 467 (73.4) 0.002**
Alterations in urination 224 (49.8) 395 (62.1) < 0.001***
Reduced libido/anorgasmia/impotence 314 (69.8) 489 (76.9) 0.008**
Difficulties in visual accommodation 321 (71.3) 494 (77.7) 0.007**
Inmunological
Recurrent low-fever 326 (72.4) 473 (74.4) 0.478
Recurrent odynophagia 306 (68.0) 477 (75.0) 0.060
Painful lymph nodes 236 (52.4) 389 (61.2) 0.061
Raynaud’s phenomenon 125 (27.8) 225 (35.4) 0.552
Generalized morning numbness 343 (76.2) 521 (81.9) 0.743
Migratory arthralgias 376 (83.6) 547 (86.0) 0.996
Allergy to multiple medications 95 (21.1) 168 (26.4) 0.011*
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on the overall score and on all three items, p < 0.001).
Unemployed patients reported greater fatigue intensity
according to the fatigue intensity scale (p < 0.001) (Table
3).
Quality of life was affected in all patients, with mean
overall scores below 45 on all SF-36 questionnaire items.
All items and physical and mental total scores indicated
significantly worse QoL in the unemployed patients. The
lowest scores were recorded for the physical role (3.1 ±
13.1 in the unemployed and 8.8 ± 20.8 in those in em-
ployment), vitality (13.2 ± 14.1 in the unemployed and
16.9 ± 14.1 in those in employment) and bodily pain
(17.3 ± 17.0 in unemployed and 24.5 ± 19.2 in those in
employment). All items showed significant differences
with p < 0.001, except for emotional role (p = 0.001) and
mental health (p = 0.012). Analyzing the total physical
and mental health scores, physical health was more af-
fected than mental health (p < 0.001 vs. p = 0.004) (Table
3). On the SCL-90-R questionnaire, unemployed patients
scored significantly worse on the three global indexes.
Of the nine items, with the exceptions of hostility and
paranoid ideation, the symptoms were significantly more
severe in the unemployed patients (Table 3). In the
HADS questionnaire, the mean scores on the anxiety
subscale were 10.7 ± 4.8 in the employed patients and
11.1 ± 4.7 in the unemployed patients (p = 0.209); on the
depression subscale, mean scores were 9.8 ± 4.8 in pa-
tients in employment and 11.3 ± 4.6 in the unemployed
(p < 0.001).
The PSQI showed that both employed and un-
employed patients with CFS/ME had poor sleep quality,
but that the unemployed individuals slept significantly
worse (p < 0.001, Table 3).
Association between potential self-reported variables and
work status in the multivariate model
Table 4 depicts the (clinical) risk factors that were signifi-
cantly associated with work disability in the sample. In the
univariate model, female age was found a differential
factor, with patients over 50 at diagnosis more likely to be
unemployed (OR = 2.21, 95% CI: 1.41–3.46; p < 0.001).
Higher age at fatigue and pain onset was associated with
work inactivity but the differences were not statistically
significant. Presenting more muscular, cognitive, neuro-
logical, autonomic and immunological symptoms was a
risk factor for unemployment. Regarding comorbidities,
FM and degenerative vertebral disease were risk factors
for being unemployed. With regard to the measures,
higher scores on the pain VAS, higher scores on the four
subscales that assess fatigue (FIS-40) and more psycho-
pathological symptoms on the SCL-90-R were predictive
risk factors for unemployment. On the HADS, scores pos-
sibly indicating symptoms were also a risk factor, as was
worse sleep quality assessed on the PSQI questionnaire. A
higher physical and/or mental QoL on the SF-36 was a
protective factor against being unemployed (Table 4). On
the other hand, the multivariate model identified age over
50 years, more autonomic symptoms, high scores on the
fatigue VAS and the D-FIS-8 and doubtful scores on the
HADS as risk predictors of work disability. Higher phys-
ical and mental QoL (assessed by SF-36) were protective
factors against being unemployed.
Discussion
This is the first large community-based study in Spain to
examine differential clinical assessment and fatigue-
related variables related with work disability in CFS/ME
patients who are unemployed at the time of diagnosis.
More than half of patients were unemployed due to tem-
porary or permanent disability. These results are consist-
ent with those of Taylor’s review published in 2005 [23]
which reported an unemployment rate of 35–69% and
also with Ross’s study [24] which recorded a figure of
54% in CFS/ME patients: in a follow-up study in 2011,
the latter authors found that the rate remained relatively
stable at 50%. In a related illness like FM, a common co-
morbidity in CFS/ME subjects, the degree of unemploy-
ment ranges between 34 and 77% [25]. Patients over 50
Table 2 Data on self-reported symptom clusters in the sample (n = 1086) (Continued)
Symptoms Employed (n = 450) Unemployed (n = 636) p-valuea
Food intolerance 41 (9.1) 78 (12.3) 0.004**
Allergy to multiple metals 51 (11.3) 110 (17.3) 0.008**
History of sinusitis 30 (6.7) 63 (9.9) 0.022*
Facial swelling 19 (4.2) 44 (6.9) 0.265
Mouth ulcers 238 (52.9) 348 (54.7) 0.044*
Herpes 226 (50.2) 313 (49.2) 0.101
Candidiasis 172 (38.2) 243 (38.2) 0.006**




a Data analysis was performed using Chi-square test for categorical variables
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Table 3 Mean scores for outcome measures as predictor variables of employment status among participants (n = 1086)
Measures Employed (n = 450) Unemployed (n = 636) p-valuea
VAS-pain 7.3 ± 1.9 7.6 ± 1.8 < 0.001***
VAS-fatigue 8.1 ± 1.0 8.4 ± 1.2 < 0.001***
FIQ 57.0 ± 7.4 59.6 ± 6.2 < 0.001***
FIS-40
Global score 123.1 ± 22.7 133.3 ± 19.8 < 0.001***
Physical 34.2 ± 4.9 36.1 ± 3.7 < 0.001***
Cognitive 30.3 ± 7.0 32.7 ± 6.9 < 0.001***
Psychosocial 58.4 ± 13.2 64.6 ± 11.2 < 0.001***
D-FIS-8 23.3 ± 5.0 25.8 ± 4.4 < 0.001***
SCL-90-R
Global severity index 1.6 ± 0.8 1.9 ± 0.8 < 0.001***
Positive symptom distress index 2.4 ± 0.5 2.6 ± 0.5 < 0.001***
Global positive symptom 59.5 ± 17.9 62.9 ± 17.6 0.002**
Somatization 2.4 ± 0.8 2.7 ± 0.8 < 0.001***
Obsessive-compulsive 2.4 ± 0.9 2.6 ± 0.9 0.001***
Interpersonal sensitivity 1.4 ± 1.0 1.5 ± 1.0 0.040*
Depression 2.0 ± 0.9 2.3 ± 0.9 < 0.001***
Anxiety 1.5 ± 1.0 1.7 ± 1.0 < 0.001***
Hostility 1.2 ± 1.0 1.2 ± 1.0 0.400
Phobic anxiety 1.1 ± 1.0 1.5 ± 1.1 < 0.001***
Paranoid ideation 1.1 ± 1.0 1.2 ± 1.0 0.544
Psychoticism 1.0 ± 0.8 1.1 ± 0.8 0.007**
HADS
Global score 20.5 ± 4.6 22.6 ± 4.5 0.002**
Anxiety 10.7 ± 4.8 11.1 ± 4.7 0.209
Depression 9.8 ± 4.8 11.3 ± 4.6 < 0.001***
PSQI
Global score 12.7 ± 4.4 14.0 ± 4.2 < 0.001***
Subjective sleep quality 2.0 ± 0.9 2.2 ± 0.9 0.001**
Sleep latency 1.9 ± 1.0 2.1 ± 0.9 0.002**
Sleep duration 1.7 ± 0.9 1.6 ± 1.0 0.037*
Habitual sleep efficiency 1.4 ± 1.2 1.7 ± 1.2 < 0.001***
Sleep disturbances 2.0 ± 0.7 2.2 ± 0.6 < 0.001***
Use of sleeping medication 1.6 ± 1.4 2.0 ± 1.4 < 0.001***
Daytime dysfunction 2.2 ± 0.9 2.2 ± 0.9 0.649
SF-36
Physical functioning 40.3 ± 21 28.5 ± 18.9 < 0.001***
Physical role 8.8 ± 20.8 3.1 ± 13.1 < 0.001***
Bodily pain 24.5 ± 19.2 17.3 ± 17 < 0.001***
General health 26.3 ± 15.9 21.3 ± 14.4 < 0.001***
Vitality 16.9 ± 14.1 13.2 ± 14.1 < 0.001***
Social role functioning 37.6 ± 24.4 26.8 ± 22.2 < 0.001***
Emotional role functioning 47.0 ± 45.5 38.3 ± 45.1 0.001***
Mental health 44.7 ± 20.7 41.6 ± 21.7 0.012*
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at the time of diagnosis and those with a later onset of
fatigue and pain have a higher risk of being unemployed.
Collin et al. [26] also associated age with unemployment.
In contrast to our study, those authors found lower per-
centage of women and higher proportions of patients
≤40 years; however, the percentage of patients who did
not work was almost similar (58.6% in our study and
65.4% in Collin et al.’s study [26]).
The presence of a larger number of symptoms was in-
dicative of unemployment in all clinical groups in the
univariate analysis. However, in the multivariate model
only autonomic dysfunction symptoms remained as a
significant predictive factor. With regard to cognitive
symptoms, more than 90% of our patients reported al-
terations in concentration, recent memory, and difficulty
with reading and arithmetic, alterations which were
more frequent in unemployed patients. These data coin-
cide with a previous study by our group, which found
also attention and information processing speed to be
impaired in female patients with CFS/ME [27].
As for comorbidities, an interesting finding was the
prevalence of FM: 62% in the unemployed compared
with 46% of those in employment. In the univariate ana-
lysis, FM patients were 92% more likely to be un-
employed than those without. A 2014 study by our team
already showed that FM worsened clinical features, fa-
tigue and QoL in CFS/ME patients [8]. Our data agree
with those of Assefi et al. [28] who observed that the
presence of FM increased unemployment (39% of CFS/
ME patients but not FM were unemployed, compared
with 66% of patients with both conditions). Other co-
morbidities such as degenerative vertebral disease and
MCS were also associated with unemployment, in ac-
cordance with Brown et al.’s study [29].
In a 2005 review article, only depression was associ-
ated with occupational dysfunction in CFS/ME, although
those authors concluded that longitudinal and interven-
tion studies were necessary to confirm their data [23]. In
the 2009 Hadlandsmyth study, depression was associated
with work absenteeism and independently with fatigue
in CFS/ME patients [30].
Our unemployed patients obtained higher scores on
the fatigue perception scales. Higher scores on these
scales emerged as a risk factor for unemployment in the
univariate analysis, while in the multivariate analysis the
association remained only for the VAS and the D-FIS-8.
These data are in line with those of Collin et al. [26] and
Knudsen et al. [31] Knudsen et al. found that patients
with disability presented more fatigue than patients who
remained in employment. Assessing fatigue with the
Chalder scale, Collin et al. [26] found higher levels in
unemployed patients, but in the multivariate analysis, fa-
tigue was not maintained as a risk factor for work dis-
ability. In the study by Palstam et al. [32], fatigue was a
symptom reported by FM patients; those in employment
reported less physical and mental fatigue, as measured
by the FIQ.
The use of the SF-36 questionnaire in CFS/ME has
been previously described by several authors. In 2011,
Nacul et al. [33] compared functional status and QoL in
CFS/ME individuals and in other chronic illnesses such
as depression, cancer and rheumatoid arthritis and
found that the patients with the worst scores in the SF-
36 were those diagnosed with CFS/ME. Other studies
published by Jason et al. sought to identify the items on
the SF-36 that best differentiate CFS/ME patients from
healthy controls [34, 35]. Emotional role was the one
with the poorest discrimination; with regard to the phys-
ical function, there were no significant differences in
non-stressful activities such as bathing or walking at a
slow pace, but differences emerged with more intense
activity [31]. Nacul et al. suggested that the physical role
item might be an adequate measure of outcome in CFS/
ME, since it was the most affected [33]. Patients in our
series had a poorer QoL (as measured by the SF-36
questionnaire) than CFS/ME patients from similar back-
grounds reported in three previous studies [33, 35–37].
As a difference, scores on the items in Nacul et al.’s
study [33] showed less variability than those of the other
comparative studies, including ours. The confluence of
the physical function score in all the studies (with the
exception of Nacul et al. [33]) is also striking. However,
the global physical and mental health scores were similar
to those reported in the Nacul et al. study [33].
The only study that associates unemployment with
QoL is the one by Collin et al. [26]; however, those
Table 3 Mean scores for outcome measures as predictor variables of employment status among participants (n = 1086) (Continued)
Measures Employed (n = 450) Unemployed (n = 636) p-valuea
Physical component 28.0 ± 7.4 24.7 ± 6.4 < 0.001***
Mental component 35.1 ± 12.7 32.9 ± 13.1 0.004**
Data are given as mean ± standard deviation (SD) in the sample
Abbreviations: VAS Visual analogue scale, FIQ Fatigue intensity questionnaire, FIS Fatigue impact scale, SCL-90-R Symptom checklist-90-revised, HADS Hospital




aData analysis using the Mann-Whitney U test for independent samples
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Table 4 Multiple lineal regression analysis for self-reported outcome measures with sex and age as dependent variables in the
sample (n = 1086)
UNIVARIATE MULTIVARIATE
Variable n OR (95% CI) p-valuea OR (95% CI) p-valuea
Gender
Female 978 1.01 (0.68–1.51) 0.959 0.97 (0.56–1.67) 0.906
Male 108 1 1
Age range, years
≤ 40 253 1 1
41–50 428 1.28 (0.94–1.75) 0.123 1.59 (1.04–2.42) 0.031*
> 50 405 1.70 (1. 23–2.34) 0.001*** 2.21 (1.41–3.46) < 0.001***
Age of pain onset
Early, ≤ 3 yrs 532 1 1
Late, > 3 yrs 520 1.44 (1. 12–1.84) 0.004** 1.49 (0.75–2.95) 0.254
VAS (fatigue/pain)
Lower 645 1 1
Higher 441 2.24 (1.73–2.89) < 0.001*** 2.09 (1.47–2.97) < 0.001***
Cognitive symptoms
Severe 846 1 1
Mild/moderate 61 1.66 (1. 30–2.13) < 0.001*** 0.28 (0.05–1.64) 0.159
No symptoms 179 0.76 (0.47–1.23) 0.077** 0.60 (0. 37-0.96) 0.033*
Neurological symptoms
Severe 606 1 1
Mild/moderate 451 1.66 (1. 30–2.13) < 0.001*** 1.37 (0.92–2.04) 0.117
No symptoms 29 0.82 (0.51–1.23) 0.214 11.02 (2. 24–54.29) 0.003**
Autonomic dysfunction
Severe 412 1 1
Mild/moderate 161 2.21 (1.71–2.87) < 0.001*** 0.22 (0.03–1.51) 0.122
No symptoms 513 0.81 (0. 37–1.76) 0.093 0.57 (0. 38–0.83) 0.004**
Fibromyalgia
No 464 1 1
Yes 601 1.92 (1.50–2.45) < 0.001*** 1.27 (0.87–1.83) 0.214
Ligamentous Hyperlaxity
No 719 1 1
Yes 365 1.45 (1. 12–1.88) 0.005** 1.36 (0.94–1.97) 0.100
SF-36 (physical health)
Lower 542 1 1
Higher 541 0.48 (0. 38–0.62) < 0.001*** 0.45 (0. 31–0.66) < 0.001***
SF-36 (mental health)
Lower 542 1 1
Higher 541 0.66 (0.52–0.84) < 0.001*** 0.50 (0. 33–0.75) < 0.001***
HADS
No symptoms 250 1 1
Mild/moderate 583 1.82 (1. 35–2.45) < 0.001*** 0.90 (0.56–1.44) 0.667
Severe 240 1.86 (1. 30–2.67) < 0.001*** 1.98 (1. 20–3.26) 0.007**
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authors measured only the physical function of the SF-
36, which was identified as a risk factor in the multivari-
ate analysis. In Palstam et al.’s study [32], patients with
FM who were in work presented better physical health
on the SF-36 scale.
Our results for the HADS scale were consistent with
those of Collin et al. [26] Similarly, women with FM
who worked obtained lower scores for depression on the
HADS than those who did not, although no differences
were observed for anxiety [32]. On the other hand, Cic-
cone [38] used the SCL-90-R as one of the variables to
differentiate between patients who improved and those
who did not. In the measurement of pain using the VAS,
our results recall those of Collin et al. [26], who found
higher VAS scores for pain in unemployed patients;
these higher VAS scores were a risk factor for un-
employment in the univariate model but not in the
multivariate models. All participants had poor sleep
quality as measured by the PSQI questionnaire. The un-
employed obtained higher scores, indicating poorer sleep
quality. Reviewing the literature, no previous studies
have assessed work-related incapacity and sleep quality
in CFS/ME individuals.
This study has several limitations and strengths. The
first limitation that we should stress is the fact that the
patients were all recruited from a tertiary-referral hos-
pital unit for CFS/ME. Most were referred from primary
care, but others were referred from a specialist care unit,
and so the population as a whole might be expected to
present more severe symptoms than if the study had
been carried out exclusively in the primary care setting.
Second, as this was a cross-sectional study, the evolution
of patients’ employment status over time could not be
assessed. Third, in unemployed patients the reason for
temporary or permanent work incapacity was unknown
(no distinction was made between full-time and part
time employment). Fourth, it is difficult to judge the sig-
nificance of these findings as no attempt was made to
compare these results with those of matched healthy
controls. One of the main strengths of this study was the
wide-cohort of CFS/ME patients who were included pro-
spectively, which allowed us to evaluate all the predictive
variables under adequate data analysis. All patients re-
cruited had CFS/ME diagnosed by a specialist; patients
with fatigue secondary to other health conditions were
excluded. In the assessment of work disability, individ-
uals whose employment status could not be assessed at
the time of diagnosis were also excluded.
Conclusions
In summary, our findings suggest that the CFS/ME
phenotype that predicts of work disability at the time of
diagnosis in a tertiary hospital CFS/ME clinical setting is
that of a woman aged over 50 years, with professional
qualifications and a medium or high educational level,
with notable neurocognitive symptoms, associated co-
morbidities, high levels of fatigue, pain, psychopathology
symptoms, sleep problems, and poor physical and
Table 4 Multiple lineal regression analysis for self-reported outcome measures with sex and age as dependent variables in the
sample (n = 1086) (Continued)
UNIVARIATE MULTIVARIATE
Variable n OR (95% CI) p-valuea OR (95% CI) p-valuea
FIS-40
Mild/moderate 512 1 1
Severe 463 2.61 (2.01–3.39) < 0.001*** 1.27 (0.82–2.04) 0.311
D-FIS-8
Lower fatigue 563 1 1
Higher fatigue 514 2.44 (1.90–3.13) < 0.001*** 1.55 (1.08–2.21) 0.017*
PSQI
Good sleepers 572 1 1
Poor sleepers 446 1.47 (1. 14–1.90) 0.003** 0.98 (0.66–1.48) 0.913
SCL-90-R
Mild/moderate 90 1 1
No symptoms 125 1.1 (0.87–1.91) 0.217 1.30 (1. 15–2.73) 0.571
Severe 430 1.98 (1.51–2.61) < 0.001*** 1.34 (0.82–2.21) 0.243
CI confidence interval, OR odds ratio, VAS Visual analogue scale, FIS Fatigue impact scale, SF-36 Short form 36-item health survey, HADS Hospital anxiety and




aData analysis using ANOVA
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mental quality of life. These data may help to guide opti-
mal functional assessment and rehabilitation therapy in
unemployed CFS/ME patients. Some possible interven-
tions and/or strategies at macro- or policy, meso- and
micro-levels frame in populations of CFS/ME sufferers
might be: 1) an adaptation of the working conditions
(hours worked, physical and cognitive effort, etc) could
be proposed - this adaptation should be personalized to
the needs of each patient with health care personnel
trained to manage the illness supported by government
policies around the world; 2) provide evidence-based
treatments with demonstrated efficacy and safety useful
in individuals who has CFS/ME, not treating the illness;
and then 3) promote cooperation programmes providing
counseling, education, information feedback, and other
supports to patients in CFS/ME clinical units from
health care system in order to improve the outcomes
both in Spain and abroad. Further additional studies are
now needed to focus on work-related disability in CFS/
ME in order to develop and support potential rehabilita-
tion strategies for this condition.
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